SCHEMBL3015722

SCHEMBL3015722

O=S(=O)(c1cccc(Cl)c1)C1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
RAB9A P51151 4/20 0.55
MAPT P10636 6/20 0.53
NPC1 O15118 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPK1 P28482 4/20 0.52
KDM1A O60341 3/20 0.52
LMNA P02545 4/20 0.47
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
FFAR2 O15552 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAOA P21397 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015016 0.94 RAB9A (0.58) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3015000 0.93 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL2999993 0.93 RAB9A (0.59) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3017336 0.91 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3005751 0.91 SMN1; SMN2 (0.55) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3009446 0.91 RAB9A (0.53) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3010751 0.91 RAB9A (0.50) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3013511 0.90 MAPT (0.56) SMN1; SMN2RAB9AMAPTNPC1MAPK1
SCHEMBL3009891 0.90 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AMAPTNPC1CYP1A2
SCHEMBL3016865 0.90 SMN1; SMN2 (0.54) SMN1; SMN2RAB9AMAPTNPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.